Search

Your search keyword '"C. Warnke"' showing total 18 results
Start Over Author "C. Warnke" Publisher springer science and business media llc
18 results on '"C. Warnke"'

4. Predictors of colonization with Staphylococcus species among patients scheduled for cardiac and orthopedic interventions at tertiary care hospitals in north-eastern Germany—a prevalence screening study

Author

Rainer Bader, Andreas Podbielski, Denis Gümbel, Axel Ekkernkamp, S. Neidhart, Sylvio Redanz, C. Güthoff, Peter C. Warnke, Romy Spitzmüller, André Göhler, V. Henck, D. Stengel, Silva Holtfreter, Sarah Zaatreh, Matthias Napp, Wolfram Mittelmeier, D. Divchev, G. Steinhoff, Christoph A. Nienaber, Annett Klinder, Martin Ellenrieder, M. AbouKoura, and A. Alozie

Subjects
Adult, Male, Methicillin-Resistant Staphylococcus aureus, 0301 basic medicine, Microbiology (medical), Thorax, medicine.medical_specialty, Adolescent, 030106 microbiology, Groin, medicine.disease_cause, Tertiary Care Centers, Young Adult, 03 medical and health sciences, Risk Factors, Germany, Internal medicine, Throat, Prevalence, medicine, Humans, Orthopedic Procedures, Colonization, Cardiac Surgical Procedures, Nose, Aged, Aged, 80 and over, Cross Infection, business.industry, General Medicine, Odds ratio, Middle Aged, Staphylococcal Infections, bacterial infections and mycoses, Cross-Sectional Studies, Infectious Diseases, medicine.anatomical_structure, Staphylococcus aureus, Carrier State, Orthopedic surgery, Pharynx, Female, Nasal Cavity, business
Abstract

As methicillin-resistant Staphylococcus aureus (MRSA) colonization and infection in humans are a global challenge. In Mecklenburg and Western Pomerania (Germany) 1,517 patients who underwent surgical interventions were systematically screened for MRSA and MSSA colonization on the day of hospital admission and discharge. Demographic data, risk factors and colonization status of the (i) nose, (ii) throat, (iii) groin, and (iv) thorax or site of surgical intervention were determined. Of the 1,433 patients who were included for further evaluation, 331 (23.1%) were colonized with MSSA, while only 17 (1.2%) were MRSA carriers on the day of hospital admission. A combination of nose, throat and groin swabs returned a detection rate of 98.3% for MSSA/MRSA. Trauma patients had lower prevalence of MRSA/MSSA (OR 0.524, 95% CI: 0.37–0.75; p

Published
2017

5. Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms

Author

J Prosser, Brian Haylock, David L Fildes, K. Kopitzki, Carol Walker, Sobhan Vinjamuri, David Husband, Kathy A. Joyce, Michael D. Jenkinson, D. G. Du Plessis, John Broome, Peter C. Warnke, and Trevor A Smith

Subjects
Male, Oncology, Cancer Research, Pathology, medicine.medical_treatment, Procarbazine, Lomustine, Antineoplastic Combined Chemotherapy Protocols, Genotype, Prospective Studies, Prospective cohort study, 18Fluorodeoxyglucose SPECT, Brain Neoplasms, 201Thallium SPECT, Middle Aged, Magnetic Resonance Imaging, Survival Rate, chemosensitivity, Treatment Outcome, Chromosomes, Human, Pair 1, Vincristine, 1p/19q loss, Disease Progression, Female, medicine.drug, Adult, medicine.medical_specialty, Oligodendroglioma, Fluorodeoxyglucose F18, Internal medicine, medicine, Humans, Genetic Predisposition to Disease, Survival rate, Alleles, Aged, Tomography, Emission-Computed, Single-Photon, Chemotherapy, business.industry, Genetics and Genomics, medicine.disease, Neoplasm Recurrence, Local, Tomography, X-Ray Computed, business, Chromosomes, Human, Pair 19
Abstract

The -1p/-19q genotype predicts chemosensitivity in oligodendroglial neoplasms, but some with intact 1p/19q also respond and not all with 1p/19q loss derive durable benefit from chemotherapy. We have evaluated the predictive and prognostic significance of pretherapy (201)Tl and (18)F-FDG SPECT and genotype in 38 primary and 10 recurrent oligodendroglial neoplasms following PCV chemotherapy. 1p/19q loss was seen in 8/15 OII, 6/15 OAII, 7/7 OIII, 3/11 OAIII and was associated with response (Fisher-Exact: P=0.000) and prolonged progression-free (log-rank: P=0.002) and overall survival (OS) (log-rank: P=0.0048). Response was unrelated to metabolism, with tumours with high or low metabolism showing response. Increased (18)F-FDG or (201)Tl uptake predicted shorter progression-free survival (PFS) in the series (log-rank: (201)Tl P=0.0097, (18)F-FDG P=0.0170) and in cases with or without the -1p/-19q genotype. Elevated metabolism was associated with shorter OS in cases with intact 1p/19q (log-rank: (18)F-FDG P=0.0077; (201)Tl P=0.0004) and shorter PFS in responders (log-rank: (18)F-FDG P=0.005; (201)Tl P=0.0132). (201)Tl uptake and 1p/19q loss were independent predictors of survival in multivariate analysis. In this initial study, (201)Tl and (18)F-FDG uptake did not predict response to PCV, but may be associated with poor survival following therapy irrespective of genotype. This may be clinically useful warranting further study.

Published
2006

6. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours

Author

Brian Haylock, John Broome, Michael D. Jenkinson, David Husband, Daniel du Plessis, Kathy A. Joyce, Carol Walker, Peter C. Warnke, Trevor S. Smith, and Diane Fildes

Subjects
Adult, Vincristine, Pathology, medicine.medical_specialty, Genotype, medicine.medical_treatment, Oligodendroglioma, Clinical Neurology, Loss of Heterozygosity, Antineoplastic Agents, Blood volume, Procarbazine, Vascularity, Predictive Value of Tests, medicine, Humans, Radiology, Nuclear Medicine and imaging, Prospective Studies, Chemosensitivity, Oligodendroglial tumour, Diagnostic Neuroradiology, Outcome, Aged, Chemotherapy, Blood Volume, medicine.diagnostic_test, Brain Neoplasms, business.industry, rCBV, Magnetic resonance imaging, Lomustine, Middle Aged, medicine.disease, Magnetic Resonance Imaging, Treatment Outcome, Radiology Nuclear Medicine and imaging, Neurology (clinical), medicine.symptom, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract

Introduction The biological factors responsible for differential chemoresponsiveness in oligodendroglial tumours with or without the −1p/−19q genotype are unknown, but tumour vascularity may contribute. We aimed to determine whether dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) could distinguish molecular subtypes of oligodendroglial tumour, and examined the relationship between relative cerebral blood volume (rCBV) and outcome following procarbazine, lomustine and vincristine (PCV) chemotherapy. Methods Pretherapy rCBV was calculated and inter- and intraobserver variability assessed. Allelic imbalance in 1p36, 19q13, 17p13, 10p12–15, and 10q22–26 and p53 mutation (exons 5–8) were determined. rCBV was compared with genotype and clinicopathological characteristics (n=37) and outcome following PCV chemotherapy (n=33). Results 1p/19q loss was seen in 6/9 grade II oligodendrogliomas, 6/14 grade II oligoastrocytomas, 4/4 grade III oligodendrogliomas, and 3/10 grade III oligoastrocytomas. rCBV measurements had good inter- and intraobserver variability, but did not distinguish histology subtype or grade. Tumours with 1p/19q loss had higher rCBV values (Student’s t-test P=0.001). Receiver operating characteristic analysis revealed a cut-off of 1.59 for identifying genotype (sensitivity 92%, specificity 76%). Tumours with high and low rCBV showed response to chemotherapy. The −1p/−19q genotype, but not rCBV, was strongly associated with response, progression-free and overall survival following PCV chemotherapy. Tumours with high rCBV and intact 1p/19q were associated with shorter progression-free and overall patient survival than those with intact 1p/19q and low rCBV or high rCBV and 1p/19q loss. Conclusion rCBV identifies oligodendroglial tumours with 1p/19q loss, but does not predict chemosensitivity. The prognostic significance of rCBV may differ in oligodendroglial tumours with or without the −1p/−19q genotype.

Published
2006

7. Expression of ADAMTS-8, a secreted protease with antiangiogenic properties, is downregulated in brain tumours

Author

A. L. Gee, Peter C. Warnke, J. E. Reed, Carol Walker, Julie R. Dunn, P. Reeves, Daniel du Plessis, and Elisabeth Shaw

Subjects
Vascular Endothelial Growth Factor A, Cancer Research, Pathology, medicine.medical_specialty, Angiogenesis, Blotting, Western, Down-Regulation, Angiogenesis Inhibitors, Cell Cycle Proteins, Biology, medicine.disease_cause, Methylation, Sensitivity and Specificity, Metastasis, Neovascularization, angiogenesis, ADAMTS Proteins, Downregulation and upregulation, Cell Line, Tumor, glioma, Glioma, ADAMTS-8, medicine, Humans, RNA, Messenger, Promoter Regions, Genetic, Binding Sites, Brain Neoplasms, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, brain tumours, ADAMTS, Genetics and Genomics, invasion, medicine.disease, ADAM Proteins, Oncology, Cancer research, Immunohistochemistry, medicine.symptom, Carcinogenesis
Abstract

Angiogenesis and extracellular matrix degradation are key events in tumour progression, and factors regulating stromal–epithelial interactions and matrix composition are potential targets for the development of novel anti-invasive/antiangiogenic therapies. Here, we examine the expression of ADAMTS-8, a secreted protease with antiangiogenic properties, in brain tissues. Using quantitative RT–polymerase chain reaction (PCR), high, equivalent expression of ADAMTS-8 was found in normal whole brain, cerebral cortex, frontal lobe, cerebellum and meninges. ADAMTS-8 expression in 34 brain tumours (including 22 high-grade gliomas) and four glioma cell lines indicated at least two-fold reduction in mRNA compared to normal whole brain in all neoplastic tissues, and no detectable expression in 14 out of 34 (41%) tumours or four out of four (100%) cell lines. In contrast, differential expression of TSP1 and VEGF was seen in nine out of 15 (60%) and seven out of 13 (54%) tumours, with no relationship in the expression of these genes. Immunohistochemistry and Western analysis indicated downregulation of ADAMTS-8 protein in >77% tumours. Methylation-specific PCR analysis of ADAMTS-8 indicated promoter hypermethylation in one out of 24 brain tumours (a metastasis) and three out of four glioma cell lines suggesting an alternative mechanism of downregulation. These data suggest a role for ADAMTS-8 in brain tumorigenesis, warranting further investigation into its role in regulation of tumour angiogenesis and local invasion.

Published
2006

8. Brachytherapy for brain tumors

Author

Philip H. Gutin, Peter C. Warnke, Todd W. Vitaz, and Viviane Tabar

Subjects
Cancer Research, medicine.medical_specialty, Radiobiology, medicine.medical_treatment, Brachytherapy, Metastasis, Glioma, medicine, Animals, Humans, Single institution, Brain Neoplasms, business.industry, Astrocytoma, Radiotherapy Dosage, medicine.disease, Surgery, Radiation therapy, Neurology, Oncology, Neurology (clinical), Radiology, business, Anaplastic astrocytoma
Abstract

Over the past several decades neurooncologists have attempted to find an adjuvant treatment that prolongs survival for patients with malignant brain tumors. Brachytherapy, radiotherapy delivered by placing radioactive sources directly into the tumor, was initially thought to be the solution to this problem. Initial single institution studies showed very promising results; however, this technique has failed to show a significant survival advantage in two randomized studies. Despite this, brachytherapy continues to be used in a number of centers throughout the world for the treatment of various types of brain tumors including low-grade gliomas, anaplastic astrocytomas, glioblastomas, meningiomas and metastases. This article reviews brachytherapy's rationale, radiobiology, complications, indications, and results from numerous studies that have focused on its application for brain tumors with emphasis on its application for glial tumors.

Published
2005

9. Follow-up of collagen crosslink excretion in patients with oral squamous cell carcinoma and analysis of tissue samples

Author

Hendrik Terheyden, Anton Dunsche, Peter C. Warnke, Ingo N.G. Springer, M Tiemann, M A A Suhr, and Yahya Açil

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Pathology, Osteolysis, Urinary system, Urine, Gastroenterology, Excretion, collagen crosslinks, chemistry.chemical_compound, pyridinoline, Internal medicine, Biomarkers, Tumor, medicine, Humans, Amino Acids, Aged, Aged, 80 and over, Mouth neoplasm, tissue samples, Pyridinoline, business.industry, Molecular and Cellular Pathology, Middle Aged, medicine.disease, Resorption, oral squamous cell carcinoma, Mandibular Neoplasms, stomatognathic diseases, Oncology, Epidermoid carcinoma, chemistry, Carcinoma, Squamous Cell, Disease Progression, Female, Mouth Neoplasms, Collagen, business
Abstract

The presence of an oral squamous cell carcinoma (OSCC) may be associated with increased urinary excretion of the markers of collagen degradation, hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP). We investigated the possibility of these markers predicting the presence of active disease. Patients from a current study on HP and LP were included as follows: Group 1a (OSCC with confirmed mandibular bony infiltration, n=12), group 1b (group 1a patients >6 months after successful treatment), group 2a (OSCC without evidence of mandibular bone infiltration, n=8), group 2b (group 2a patients >6 months after successful treatment), group 3a (recurrent OSCC, n=8), group 3b (group 3a patients >6 weeks later, symptoms unchanged) and group 4 (control group, n=74). Tissue samples from tumour tissue and adjacent healthy mucosa were additionally investigated for HP and LP concentrations (n=8). The decrease in the urinary concentrations of HP and LP was statistically significant between groups 1a and 1b (P

Published
2003

10. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene — a phase I/II clinical protocol

Author

K. Lundstrom, A. Söling, Nikolai G. Rainov, T. Boulikas, Peter C. Warnke, and Huan Ren

Subjects
Adult, Male, Cancer Research, Pathology, medicine.medical_specialty, Magnetic Resonance Spectroscopy, medicine.medical_treatment, Genetic Vectors, Brain tumor, Capsules, Virus Replication, Semliki Forest virus, medicine, Humans, Vector (molecular biology), Cerebellar Neoplasms, Chemotherapy, biology, business.industry, Standard treatment, Genetic Therapy, biology.organism_classification, medicine.disease, Interleukin-12, Magnetic Resonance Imaging, Semliki forest virus, Primary tumor, nervous system diseases, Neurology, Oncology, Viral replication, Liposomes, Interleukin 12, Cancer research, Female, Immunotherapy, Neurology (clinical), Neoplasm Recurrence, Local, Glioblastoma, business
Abstract

Glioblastoma multiforme (GBM) is an incurable brain tumor resistant to standard treatment modalities such as surgery, radiation, and chemotherapy. Since recurrent GBM tends to develop predominantly within the infiltrative rim surrounding the primary tumor focus, novel therapy strategies need in addition to focal tumor destruction to target this somewhat diffuse area. This is a phase I/II clinical study in adult patients with recurrent GBM which is aimed at evaluating biological safety, maximum tolerated dose, and antitumor efficacy of a genetically modified replication-disabled Semliki forest virus vector (SFV) carrying the human interleukin 12 (IL-12) gene and encapsulated in cationic liposomes (LSFV-IL12). The vector will be administered in doses of 1 x 10(7)-1 x 10(9) infectious particles by continuous intratumoral infusion, thus exploiting the advantages of convection-enhanced drug delivery in the brain. The present protocol is also designed to investigate systemic and local immune response and to identify factors predicting tumor response to LSFV-IL12 therapy, such as volume of extracellular space of the tumor, volume of contrast enhancing lesion, and immune status of the patients. SFV, an insect alphavirus, infects mitotic and non-mitotic cells and triggers apoptosis in tumor cells within 48-72 h. Preclinical work with the LSFV-IL12 vector in breast and prostate cancer animal models demonstrated its biosafety and some antitumor efficacy. An ongoing phase I clinical study in patients with melanoma and renal cell carcinoma seems also to confirm the biosafety of intravenously administered vectors. This protocol will be the first study of SFV-IL12 therapy of human recurrent GBM.

Published
2003

11. Neuronavigation

Author

Ostertag Cb and Peter C. Warnke

Subjects
medicine.medical_specialty, Neuronavigation, Neurology, General Medicine, Gold standard (test), Maximum error, Resection, Lesion, Psychiatry and Mental health, Stereotaxy, medicine, Neurology (clinical), Radiology, Neurosurgery, medicine.symptom
Abstract

The use of stereotactic methods for the resection of subcortical lesions is heavily advocated in clinical neurosurgery introducing the term "neuronavigation". Though being an unequivocally elegant technique for the localisation and delineation of pathological lesions in the central nervous system neuronavigation has not been validated by any prospective randomized controlled trial. The method is prone to significant errors as to the intraoperative localisation based upon preoperative three-dimensional images. The maximum error can be up to 2.6 cm depending on the extent of the so-called brain shift. In comparison classical frame based stereotaxy has a mean error of +/- 1 mm and remains the gold standard for the exact three-dimensional localisation of a given lesion. The value of neuronavigation is evident for small deep seated vascular lesions. For metastatic tumors or skull base tumors the usefulness is rather marginal because alternative therapies are available with proven and equivalent efficacy and reduced morbidity on one hand, and because of the anatomy of the tumor which makes neuronavigation unnecessary. For the currently most common application of neuronavigation, i.e. surgery of gliomas, no significant improvements of therapeutic results can be expected from neuronavigation. The biology of gliomas limits any mechanical approaches.

Published
1999

12. European Society for Stereotactic and Functional Neurosurgery

Author

D. A. Bosch, G. Broggi, H. A. C. Cockburn, Ch. B. Ostertag, Bengt Linderoth, D. G. T. Thomas, and P. C. Warnke

Subjects
medicine.medical_specialty, Neurology, medicine.diagnostic_test, business.industry, Medicine, Surgery, Medical physics, Interventional radiology, Neurology (clinical), Neurosurgery, Functional neurosurgery, business, Neuroradiology
Published
1998

13. [Untitled]

Author

Peter C. Warnke and Karl H. Plate

Subjects
Cancer Research, Endothelium, Angiogenesis, Vascular permeability, Biology, Hypoxia (medical), Vascular endothelial growth factor, Neovascularization, Vascular endothelial growth factor B, chemistry.chemical_compound, medicine.anatomical_structure, Neurology, Oncology, chemistry, Immunology, medicine, Cancer research, Neurology (clinical), medicine.symptom, Signal transduction
Abstract

Vascular endothelial growth factor (VEGF) is a hypoxia-inducible angiogenesis and vascular permeability factor which is expressed in high amounts in perinecrotic palisading cells in human glioblastomas. In vitro VEGF gene expression is enhanced approximately ten times by hypoxia. Current evidence suggests, that hypoxia is also the driving force for VEGF gene expression in glioblastoma cells in vivo and represents the most important trigger for tumor angiogenesis and edema. Our approaches to inhibit tumor angiogenesis and edema formation in glioblastoma patients will concentrate on the disruption of VEGF/VEGF receptor signal transduction pathway in vivo.

Published
1997

14. The effects of dexamethasone on transcapillary transport in experimental brain tumors: II. Canine brain tumors

Author

Gregory D. Lapin, Peter Molnar, Dennis R. Groothuis, Abraham Kuruvilla, and Peter C. Warnke

Subjects
Cancer Research, medicine.medical_specialty, Antineoplastic Agents, Hormonal, medicine.drug_class, medicine.medical_treatment, Astrocytoma, Blood–brain barrier, Canine brain tumors, Avian sarcoma virus, Dexamethasone, Cerebral edema, Dogs, Internal medicine, medicine, Animals, Chemotherapy, biology, Brain Neoplasms, business.industry, Fissipedia, Models, Cardiovascular, biology.organism_classification, medicine.disease, Capillaries, Kinetics, medicine.anatomical_structure, Endocrinology, Avian Sarcoma Viruses, Neurology, Oncology, Regional Blood Flow, Regression Analysis, Corticosteroid, Sarcoma, Experimental, Neurology (clinical), Tomography, X-Ray Computed, business, Mathematics, medicine.drug
Abstract

We studied the effect of dexamethasone on transcapillary transport in ten Avian Sarcoma Virus (ASV)-induced canine brain tumors, before and one week after administration of dexamethasone, 2.5 mg/kg/day. A computed tomographic (CT) method was used to measure regional values of K1 (blood-to-tissue transfer constant), k2 (tissue-to-blood efflux constant), and Vp (tissue plasma vascular space) of meglumine iothalamate (Conray-60); the values were reconstructed for each 0.8 x 0.8 x 5 mm volume element of the CT data. For all tumors considered together, there was a decrease in the whole tumor K1 value of meglumine iothalamate from 26 +/- 2.2 (SE) before dexamethasone to 24 +/- 2.9 microliters/g/min after dexamethasone. Vp decreased from 7.2 +/- 0.7 to 6.7 +/- 0.9 ml/100 g, and the size of the tumor extracellular space (Ve) decreased from 0.30 to 0.26 ml/g. These changes were not statistically significant. However, when each tumor was used as its own control, K1 significantly decreased after dexamethasone in four tumors, significantly increased in two and was unchanged in four. These results suggest that decreased blood-to-tissue transport may be one mechanism underlying resolution of tumor associated cerebral edema in some brain tumors and that the effects of dexamethasone on blood-to-tissue transport in brain tumors are variable from one tumor to the next. Decreased 'permeability' may not be the sole mechanism by which dexamethasone reduces tumor-associated cerebral edema.

Published
1995

15. Interstitial 125-iodine radiosurgery of low-grade gliomas of the insula of Reil

Author

Faist M, Ch. B. Ostertag, Benedikt Volk, Peter C. Warnke, Friedrich W. Kreth, and Ch. R. Schätz

Subjects
Adult, Male, medicine.medical_specialty, Multivariate analysis, Adolescent, medicine.medical_treatment, Astrocytoma, Radiosurgery, Postoperative Complications, medicine, Humans, Child, Survival rate, Retrospective Studies, Cause of death, Cerebral Cortex, Neurologic Examination, Brain Neoplasms, business.industry, Proportional hazards model, Glioma, Middle Aged, Survival Rate, Radiation therapy, Child, Preschool, Relative risk, Female, Surgery, Neurology (clinical), Radiology, Neurosurgery, Tomography, X-Ray Computed, Nuclear medicine, business, Follow-Up Studies
Abstract

Between 1979 and 1991 67 patients with low-grade gliomas of the insula (of Reil) were treated with 125-iodine interstitial radiosurgery. Retrospective analysis with a median follow-up of 55 months demonstrated a 5- and 10-year survival rate of 54% and 47%, respectively, for all low-grade gliomas treated and a 5- and 10-year survival rate of 57% for 49 patients with astrocytomas WHO grade II analysed separately. The median Karnofsky performance status of survivors was 90%. Malignant change was the cause of death in 85%, failure to control tumour growth in the remaining cases. Multivariate analysis with a Cox proportional hazard model identified solely the pre-operative Karnofsky performance score of 70-80 vs. 90% as a prognostic factor for outcome (p = 0.001, risk ratio 3.62), but not age, gender, tumour volume, length of disease before treatment, mode of implantation, or major vs. moderate or no shrinkage of tumour volume after interstitial radiosurgery. Thus, 125-iodine radiosurgery yielded survival rates in these deep-seated insular gliomas comparable to those reported after surgery and radiation therapy of lobar tumours. This was achieved with a low peri-operative mortality and morbidity and at low costs.

Published
1994

16. Abstracts

Author

J. M. Derlon, M. C. Petit-taboué, F. Dauphin, P. Courtheoux, F. Chapon, P. Creissard, F. Darcel, J. P. Houtteville, B. Kaschten, B. Sadzot, A. Stevenaert, Juri G. Tjuvajev, Homer A. Macapinlac, Farhad Daghighian, James Z. Ginos, Ronald D. Finn, M. S. Jiaju Zhang, Bradley Beattie, Martin Graham, Steven M. Larson, Ronald G. Blasberg, M. Levivier, S. Goldman, B. Pirotte, J. M. Brucher, D. Balériaux, A. Luxen, J. Hildebrand, J. Brotchi, K. G. Go, R. L. Kamman, E. L. Mooyaart, M. A. A. M. Heesters, P. E. Sijens, M. Oudksrk, P. van Dijk, P. C. Levendag, Ch. J. Vecht, R. J. Metz, D. N. Kennedy, B. R. Rosen, F. H. Hochberg, A. J. Fishman, P. A. Filipek, V. S. Caviness, M. W. Gross, F. X. Weinzierl, A. E. Trappe, W. E. Goebel, A. M. Frank, Georg Becker, Andreas Krone, Karsten Schmidt, Erich Hofmann, Ulrich Bogdahn, H. Bencsch, S. Fclber, G. Finkenstedt, C. Kremser, G. Sfockhammer, F. Aichner, U. Bogdahn, T. Fröhlich, G. Becker, A. Krone, R. Schlief, J. Schürmann, P. Jachimczak, E. Hofmann, W. Roggendorf, K. Roosen, C. M. Carapella, G. Carpinelli, R. Passalacqua, L. Raus, M. Giannini, R. Mastrostefano, F. Podo, A. Tofani, R. Maslrostefano, M. Mottoles, A. Ferraironi, M. G. Scelsa, P. Oppido, A. Riccio, C. L. Maini, L. Collombier, L. Taillandier, M. Dcbouverie, M. H. Laurens, P. Thouvenot, M. Weber, A. Bertrand, G. S. Cruickshank, J. Patterson, D. Hadley, Olivier De Witte, Jerzy Hildebrand, André Luxen, Serge Goldman, R. -I. Ernestus, K. Bockhorst, M. Eis, T. Els, M. Hoehn-Berlage, M. Gliese, R. Fründ, A. Geissler, C. Woertgen, M. Holzschuh, O. Hausmann, A. Merlo, E. Jerrnann, J. Uirich, R. Chiquet-Ehrismann, J. Müller, H. Mäcke, O. Gratzl, K. Herholz, M. Ghaemi, M. Würker, U. Pietrzyk, W. -D. Heiss, K. Kotitschke, M. Brandl, J. C. Tonn, A. Haase, S. Muigg, S. Felber, M. Woydt, Heinrich Lanfermann, Walter Heindel, Harald Kugel, Ralf -Ingo Erneslus, Gabricle Röhn, Klaus Lackner, F. S. Pardo, S. Kutke, A. G. Sorensen, L. L. Mechtler, S. Withiam-Lench, K. Shin, W. R. Klnkel, M. Patel, B. Truax, P. Kinkel, L. Mechtler, M. Ricci, P. Pantano, A. Maleci, S. Pierallini, D. Di Stefano, L. Bozzao, G. P. Cantore, Gabriele Röhn, R. Schröder, R. Ruda, C. Mocellini, R. Soffietti, M. Campana, R. Ropolo, A. Riva, P. G. de Filippi, D. Schiffer, D. Salgado, M. Rodrigues, L. Salgado, A. T. Fonseca, M. R. Vieira, J. M. Bravo Marques, H. Satoh, T. Uozumi, K. Kiya, K. Kurisu, K. Arita, M. Sumida, F. Ikawa, Tz. Tzuk-Shina, J. M. Gomori, R. Rubinstein, A. Lossos, T. Siegal, W. Vaalburg, A. M. J. Paans, A. T. M. Willemsen, A. van Waarde, J. Pruim, G. M. Visser, S. Valentini, Y. L. T. Ting, R. De Rose, G. Chidichimo, G. Corricro, Karin van Lcycn-Pilgram, Ralf -Ingo Erncslus, Norfried Klug, K. van Leyen-Pilgram, N. Klug, U. Neumann, Karl H. Plate, Georg Breier, Birgit Millaucr, Herbert A. Weich, Axel Ullrich, Werner Risau, N. Roosen, R. K. Chopra, T. Mikkelsen, S. D. Rosenblum, P. S. Yan, R. Knight, J. Windham, M. L. Rosenblum, A. Attanasio, P. Cavalla, A. Chio, M. T. Giordana, A. Migheli, V. Amberger, T. Hensel, M. E. Schwab, Luigi Cervoni, Paolo Celli, Roberto Tarantino, C. Huettner, U. Berweiler, I. Salmon, S. Rorive, K. Rombaut, J. Haot, R. Kiss, C. Maugard-Louboutin, J. Charrier, G. Fayet, C. Sagan, P. Cuillioere, G. Ricolleau, S. Martin, D. Menegalli-Bogeelli, Y. Lajat, F. Resche, Péter Molnàr, Helga Bárdos, Róza Ádány, J. P. Rogers, G. J. Pilkington, B. Pollo, G. Giaccone, A. Allegranza, O. Bugiani, J. Prim, J. Badia, E. Ribas, F. Coello, E. Shezen, O. Abramsky, M. Scerrati, R. Roselli, M. Iacoangeli, A. Pompucci, G. F. Rossi, Saleh M. Al. Deeb, Osama Koreich, Basim Yaqub, Khalaf R. Al. Moutaery, S. Marino, M. C. Vigliani, V. Deburghgraeve, D. Gedouin, M. Ben Hassel, Y. Guegan, B. Jeremic, D. Grujicic, V. Antunovic, M. Matovic, Y. Shibamoto, Merja Kallio, Helena Huhmar, Ch. Kudoh, A. Detta, K. Sugiura, E. R. Hitchcock, R. Di Russo, M. Cipriani§, E. M. Occhipinti, E. M. S. Conti, A. Clowegeser, M. Ortler, M. Seiwald, H. Kostron, B. Rajan, G. Ross, C. Lim, S. Ashlcy, D. Goode, D. Traish, M. Brada, G. A. C. vd Sanden, L. J. Schouten, J. W. W. Coebergh, P. P. A. Razenberg, A. Twijnstra, A. Snilders-Keilholz, J. H. C. Voormolen, J. Hermans, J. W. H. Leer, F. Baylac, M. Dcbouvcrie, R. Anxionnal, S. Bracard, J. M. Vignand, A. Duprcz, M. Winking, D. K. Böker, T. Simmet, David Rothbart, John Strugar, Jeroen Balledux, Gregory R. Criscuolo, Piotr Jachimczak, Armin Blesch, Birgit Heβdörfer, Ralf -Ingo Ernestus, Roland Schröder, Norfrid Klug, H. G. J. Krouwer, S. G. v. Duinen, A. Algra, J. Zentner, H. K. Wolf, B. Ostertun, A. Hufnagel, M. G. Campos, L. Solymosi, J. Schramm, E. S. Newlands, S. M. O'Reilly, M. Brampton, R. Sciolla, D. Seliak, R. Henriksson, A. T. Bergenheim, P. Björk, P. -O. Gunnarsson, Ml. Hariz, R. Grant, D. Collie, A. Gregor, K. P. Ebmeier, G. Jarvis, F. Lander, A. Cull, R. Sellar, C. Thomas, S. Elyan, F. Hines, S. Ashley, S. Stenning, J. J. Bernstein, W. J. Goldberg, U. Roelcke, K. Von Ammon, E. W. Radu, D. Kaech, K. L. Leenders, M. M. Fitzek, J. Efird Aronen, F. Hochberg, M. Gruber, E. Schmidt, B. Rosen, A. Flschman, P. Pardo, U. M. U. Afra, L. Sipos, F. Slouik, A. Boiardi, A. Salmaggi, A. Pozzi, L. Farinotti, L. Fariselli, A. Silvani, A. Brandes, E. Scelzi, A. Rigon, P. Zampieri, M. Pignataro, P. D'. Amanzo, P. Amista, A. Rotilio, M. V. Fiorentino, R. Thomas, L. Brazil, A. M. O'Connor, Maurizio Salvati, Fabrizio Puzzilli, Michele Raguso, R. Duckworth, R. Rumpling, M. Rottuci, G. Broggi, N. G. Plrint, E. Sabattini, V. Manetto, H. Gambacorta, S. Poggi, S. Pileri, R. Ferracini, D. V. Plev, N. J. Hopf, E. Knosp, J. Bohl, A. Perncczky, I. Catnby, O. Dewitte, J. L. Pasteels, I. Camby, F. Darro, A. Danguy, M. C. Kiu, G. M. Lai, T. S. Yang, K. T. Ng, J. S. Chen, C. N. Chang, W. M. Leung, Y. S. Ho, M. Deblec Rychter, A. Klimek, P. P. Liberski, A. Karpinaka, P. Krauseneck, V. Schöffel, B. Müller, F. W. Kreth, M. Faist, P. C. Warnke, C. B. Ostertag, K. M. B. v. Nielen, M. C. Visscr, C. Lebrun, M. Lonjon, T. Desjardin, J. F. Michiels, Sa. Lagrange J. L. Chanalet, J. L. Roche, M. Chatel, L. Mastronardi, F. Puzzilli, Farah J. Osman, P. Lunardi, M. Matsutani, Y. Ushio, K. Takakura, Johan Menten, Han Hamers, Jacques Ribot, René Dom, Hans Tcepen, N. Weidner, G. Naujocks, D. van Roost, O. D. Wiestler, A. Kuncz, C. Nieder, M. Setzel-Sesterhein, M. Niewald, I. Schnabel, K. S. O'Neill, N. D. Kitchen, P. R. Wilkins, H. T. Marsh, E. Pierce, R. Doshi, R. Deane, S. Previtali, A. Quattrini, R. Nemni, A. Ducati, L. Wrabetz, N. Canal, C. J. A. Punt, L. Stamatakis, B. Giroux, E. Rutten, Matthew R. Quigley, P. A. -C. Beth Sargent, Nicholas Flores, Sheryl Simon, Joseph C. Maroon, A. A. Rocca, C. Gervasoni, A. Castagna, P. Picozzi, E. Giugni, G. P. Tonnarelli, F. Mangili, G. Truci, M. Giovanelli, W. Sachsenheimer, T. Bimmler, H. Rhomberg W. Eiter, A. Obwegesser, H. Steilen, W. Henn, J. R. Moringlane, H. Kolles, W. Feiden, K. D. Zang, W. I. Sleudel, Andreas Steinbrecher, Martin Schabet, Clemens Heb, Michael Bamberg, Johannes Dichgans, G. Stragliotto, J. Y. Delattre, M. Poisson, L. Tosatto, P. D'Amanzo, N. Menicucci, S. Mingrino, W. I. Steudel, R. Feld, J. Ph. Maire, M. Caudry, J. Guerin, D. Celerier, N. Salem, H. Demeaux, J. F. Fahregat, M. E. Kusak, A. Bucno, J. Albisua, P. Jerez, J. L. Sarasa, R. Garefa, J. M. de Campos, A. Bueno, R. García-Delgado, R. García-Sola, A. A. Lantsov, T. I. Shustova, D. Lcnartz, R. Wellenreuther, A. von Deirnling, W. Köning, J. Menzel, S. Scarpa, A. Manna, M. G. Reale, P. A. Oppido, L. Frati, C. A. Valery, M. Ichen, J. P. Foncin, C. Soubrane, D. Khayat, J. Philippon, R. Vaz, C. Cruz, S. Weis, D. Protopapa, R. März, P. A. Winkler, H. J. Reulen, K. Bise, E. Beuls, J. Berg, W. Deinsberger, M. Samii, V. Darrouzet, J. Guérin, R. Trouette, N. Causse, J. P. Bébéar, F. Parker, J. N. Vallee, R. Carlier, M. Zerah, C. Lacroix-Jousselin, Joseph M. Piepmeier, John Kveton, Agnes Czibulka, G. S. Tigliev, M. P. Chernov, L. N. Maslova, José M. Valdueza, Werner Jänisch, Alexander Bock, Lutz Harms, E. M. Bessell, F. Graus, J. Punt, J. Firth, T. Hope, Osama Koriech, Saleh Al Deeb, Khalaf Al Moutaery, B. Yaqub, A. Franzini, R. Goldbrunner, M. Warmuth-Metz, W. Paulus, J. -Ch. Tonn, I. I. Strik, C. Markert, K. -W. Pflughaupt, B. P. O'Neill, R. P. Dinapoli, J. Voges, V. Sturm, U. Deuß, C. Traud, H. Treuer, R. Lehrke, D. G. Kim, R. P. Müller, Yu. S. Alexandrov, K. Moutaery, M. Aabed, O. Koreich, G. M. Ross, D. Ford, I. L. O. Schmeets, J. J. Jager, M. A. G. Pannebakker, J. M. A. de Jong, E. van Lindert, K. Kitz, S. Blond, F. Dubois, R. Assaker, M. C. Baranzelli, M. Sleiman, J. P. Pruvo, B. Coche-Dequeant, K. Sano, G. PetriČ-Grabnar, B. Jereb, N. Župančič, M. Koršič, N. G. Rainov, W. Burkert, Yukitaka Ushio, Masato Kochi, Youichi Itoyama, R. García, L. Ferrando, K. Hoang-Xuan, M. Sanson, P. Merel, O. Delattre, G. Thomas, D. Haritz, B. Obersen, F. Grochulla, D. Gabel, K. Haselsberger, H. Radner, G. Pendl, R. W. Laing, A. P. Warrington, P. J. C. M. Nowak, I. K. K. Kolkman-Deurloo, A. G. Visser, Hv. d. Berge, C. G. J. H. Niël, P. Bergström, M. Hariz, P. -O. Löfroth, T. Bergenheim, C. Cortet-rudelli, D. Dewailly, B. Coche-dequeant, B. Castelain, R. Dinapoli, E. Shaw, R. Coffey, J. Earle, R. Foote, P. Schomberg, D. Gorman, N. Girard, M. N. Courel, B. Delpech, G. M. Friehs, O. Schröttner, R. Pötter, R. hawliczek, P. Sperveslage, F. J. Prott, S. Wachter, K. Dieckmann, B. Bauer, R. Jund, F. Zimmermann, H. J. Feldmann, P. Kneschaurek, M. Molls, G. Lederman, J. Lowry, S. Wertheim, L. Voulsinas, M. Fine, I. Voutsinas, G. Qian, H. Rashid, P. Montemaggi, R. Trignani, C. West, W. Grand, C. Sibata, D. Guerrero, N. James, R. Bramer, H. Pahlke, N. Banik, M. Hövels, H. J. J. A. Bernsen, P. F. J. W. Rijken, B. P. J. Van der Sanden, N. E. M. Hagemeier, A. J. Van der Kogel, P. J. Koehler, H. Verbiest, J. Jager, A. McIlwrath, R. Brown, C. Mottolesb, A. Pierre'Kahn, M. Croux, J. Marchai, P. Delhemes, M. Tremoulet, B. Stilhart, J. Chazai, P. Caillaud, R. Ravon, J. Passacha, E. Bouffet, C. M. F. Dirven, J. J. A. Mooy, W. M. Molenaar, G. M. Lewandowicz, N. Grant, W. Harkness, R. Hayward, D. G. T. Thomas, J. L. Darling, N. Delepine, I. I. Subovici, B. Cornille, S. Markowska, JC. Desbois Alkallaf, J. KühI, D. Niethammer, H. J. Spaar, A. Gnekow, W. Havers, F. Berthold, N. Graf, F. Lampert, E. Maass, R. Mertens, V. Schöck, A. Aguzzi, A. Boukhny, S. Smirtukov, A. Prityko, B. Hoiodov, O. Geludkova, A. Nikanorov, P. Levin, B. D'haen, F. Van Calenbergh, P. Casaer, R. Dom, J. Menten, J. Goffin, C. Plets, A. Hertel, P. Hernaiz, C. Seipp, K. Siegler, R. P. Baum, F. D. Maul, D. Schwabe, G. Jacobi, B. Kornhuber, G. Hör, A. Merzak, H. K. Rooprai, P. Bullock, P. H. M. F. van Domburg, P. Wesseling, H. O. M. Thijssen, J. E. A. Wolff, J. Boos, K. H. Krähling, V. Gressner-Brocks, H. Jürgens, J. Schlegel, H. Scherthan, N. Arens, Gabi Stumm, Marika Kiessling, S. Koochekpour, G. Reifenberger, J. Reifenberger, L. Liu, C. D. James, W. Wechsler, V. P. Collins, Klaus Fabel-Schulte, Plotr Jachimczak, Birgitt Heßdörfer, Inge Baur, Karl -Hermann Schlingensiepen, Wolgang Brysch, A. Blesch, A. K. Bosserhoff, R. Apfel, F. Lottspeich, R. Büttner, R. Cece, I. Barajon, S. Tazzari, G. Cavaletti, L. Torri-Tarelli, G. Tredici, B. Hecht, C. Turc-Carel, R. Atllas, P. Gaudray, J. Gioanni, F. Hecht, J. A. Rey, M. J. Bello, M. Parent, P. Gosselin, J. L. Christiaens, J. R. Schaudies, M. Janka, U. Fischer, E. Meese, M. Remmelink, P. Cras, R. J. Bensadoun, M. Frenay, J. L. Formento, G. Milano, J. L. Lagrange, P. Grellier, J. -Y. Lee, H. -H. Riese, J. Cervós-Navarro, W. Reutter, B. Lippitz, C. Scheitinger, M. Scholz, J. Weis, J. M. Gilsbach, L. Füzesi, Y. J. Li, R. Hamelin, Erik Van de Kelft, Erna Dams, Jean -Jacques Martin, Patrick Willems, J. Erdmann, R. E. Wurm, S. Sardell, J. D. Graham, Jun -ichi Kuratsu, M. Aichholzer, K. Rössler, F. Alesch, A. Ertl, P. S. Sorensen, S. Helweg-Larsen, H. Mourldsen, H. H. Hansen, S. Y. El Sharoum, M. W. Berfelo, P. H. M. H. Theunissen, I. Fedorcsák, I. Nyáry, É. Osztie, Á. Horvath, G. Kontra, J. Burgoni-chuzel, P. Paquis, SW. Hansen, PS. Sørensen, M. Morche, F. J. Lagerwaard, W. M. H. Eijkenboom, P. I. M. Schmilz, S. Lentzsch, F. Weber, J. Franke, B. Dörken, G. Schettini, R. Qasho, D. Garabello, S. Sales, R. De Lucchi, E. Vasario, X. Muracciole, J. Régis, L. Manera, J. C. Peragut, P. Juin, R. Sedan, K. Walter, K. Schnabel, N. Niewald, U. Nestle, W. Berberich, P. Oschmann, R. D. Theißen, K. H. Reuner, M. Kaps, W. Dorndorf, K. K. Martin, J. Akinwunmi, A. Kennedy, A. Linke, N. Ognjenovic, A. I. Svadovsky, V. V. Peresedov, A. A. Bulakov, M. Y. Butyalko, I. G. Zhirnova, D. A. Labunsky, V. V. Gnazdizky, I. V. Gannushkina, M. J. B. Taphoorn, R. Potman, F. Barkhof, J. G. Weerts, A. B. M. F. Karim, J. J. Heimans, M. van de Pol, V. C. van Aalst, J. T. Wilmink, J. J. van der Sande, W. Boogerd, R. Kröger, A. Jäger, C. Wismeth, A. Dekant, W. Brysch, K. H. Schlingensiepen, B. Pirolte, V. Cool, C. Gérard, J. L. Dargent, T. Velu, U. Herrlinger, M. Schabet, P. Ohneseit, R. Buchholz, Jianhong Zhu, Regina Reszka, Friedrich Weber, Wolfgang Walther, L. I. Zhang, Mario Brock, J. P. Rock, H. Zeng, J. Feng, J. D. Fenstermacher, A. Gabizon, M. Beljanski, S. Crochet, B. Zackrisson, J. Elfverson, G. Butti, R. Baetta, L. Magrassi, M. R. De Renzis, M. R. Soma, C. Davegna, S. Pezzotta, R. Paoletti, R. Fumagalli, L. Infuso, A. A. Sankar, G. -L. Defer, P. Brugières, F. Gray, C. Chomienne, J. Poirier, L. Degos, J. D. Degos, Bruno M. Colombo, Stefano DiDonato, Gaetano Finocchiaro, K. M. Hebeda, H. J. C. M. Sterenborg, A. E. Saarnak, J. G. Wolbers, M. J. C. van Gemert, P. Kaaijk, D. Troost, S. Leenstra, P. K. Das, D. A. Bosch, B. W. Hochleitner, A. Obwegeser, W. Vooys, G. C. de Gast, J. J. M. Marx, T. Menovsky, J. F. Beek, V. Schirrmacher, A. Schmitz, A. M. Eis-Hübinger, p. h. Piepmeier, Patricia Pedersen, Charles Greer, Tommy Shih, Amr Elrifal, William Rothfus, L. Rohertson, R. Rampling, T. L. Whoteley, J. A. Piumb, D. J. Kerr, P. A. Falina, I. M. Crossan, K. L. Ho, M. M. Ruchoux, S. Vincent, F. Jonca, J. Plouet, M. Lecomte, D. Samid, A. Thibault, Z. Ram, E. H. Oldfield, C. E. Myers, E. Reed, Y. Shoshan, Tz. Siegal, G. Stockhammer, M. Rosenblum, F. Lieberman, A. J. A. Terzis, R. Bjerkvig, O. D. Laerum, H. Arnold, W. D. Figg, G. Flux, S. Chittenden, P. Doshi, D. Bignor, M. Zalutsky, Juri Tjuvajev, Michael Kaplitt, Revathi Desai, M. S. Bradley, B. S. Bettie, Bernd Gansbacher, Ronald Blasberg, H. K. Haugland, J. Saraste, K. Rooseni, A. J. P. E. Vincent, C. J. J. Avezaat, A. Bout, J. L. Noteboom, C. h. Vecht, D. Valerio, P. M. Hoogerbrugge, R. Reszka, J. Zhu, W. Walther, J. List, W. Schulz, I. I. J. C. M. Sterenborg, W. Kamphorst, H. A. M. van Alplien, P. Salander, R. Laing, B. Schmidt, G. Grau, T. Bohnstedt, A. Frydrych, K. Franz, R. Lorenz, F. Berti, A. Paccagnella, P. L. van Deventer, P. L. I. Dellemijn, M. J. van den Bent, P. J. Kansen, N. G. Petruccioli, E. Cavalletti, B. Kiburg, L. J. Müller, C. M. Moorer-van Delft, H. H. Boer, A. Pace, L. Bove, A. Pietrangeli, P. Innocenti, A. Aloe, M. Nardi, B. Jandolo, S. J. Kellie, S. S. N. De Graaf, H. Bloemhof, D. Roebuck, Pozza L. Dalla, D. D. R. Uges, I. Johnston, M. Besser, R. A. Chaseling, S. Koeppen, S. Gründemann, M. Nitschke, P. Vieregge, E. Reusche, P. Rob, D. Kömpf, T. J. Postma, J. B. Vermorken, R. P. Rampling, D. J. Dunlop, M. S. Steward, S. M. Campbell, S. Roy, P. H. E. Hilkens, J. Verweij, W. L. J. van Putten, J. W. B. Moll, M. E. L. van der Burg, A. S. T. Planting, E. Wondrusch, U. Zifko, M. Drlicek, U. Liszka, W. Grisold, B. Fazeny, Ch. Dittrich, Jan J. Verschuuren, Patricio I. Meneses, Myrna R. Rosenfeld, Michael G. Kaplitt, Jerome B. Posner, Josep Dalmau, P. A. E. Sillevis Smitt, G. Manley, J. B. Posner, G. Bogliun, L. Margorati, G. Bianchi, U. Liska, B. Casati, C. Kolig, H. Grisold, R. Reñe, M. Uchuya, F. Valldeoriola, C. Benedetti de Cosentiro, D. Ortale, R. Martinez, J. Lambre, S. Cagnolati, C. Vinai, M. G. Forno, R. Luksch, P. Confalonieri, J. Scholz, G. Pfeiffer, J. Netzer, Ch. Hansen, Ch. Eggers, Ch. Hagel, K. Kunze, Marc K. Rosenblum, and Frank S. Lieberman

Subjects
Cancer Research, Neurology, Oncology, Neurology (clinical)
Published
1994

17. Blood flow and blood-to-tissue transport in 9L gliosarcomas: the role of the brain tumor model in drug delivery research

Author

Robin D. Fross, Dennis R. Groothuis, and Peter C. Warnke

Subjects
Cancer Research, Pathology, medicine.medical_specialty, Gliosarcoma, Brain tumor, Models, Biological, Drug Delivery Systems, Glioma, Cortex (anatomy), Tumor Cells, Cultured, medicine, Animals, Humans, Brain Neoplasms, business.industry, Brain, Biological Transport, Rats, Inbred Strains, Equipment Design, Neoplasms, Experimental, Blood flow, medicine.disease, Rats, Inbred F344, Pathophysiology, Rats, medicine.anatomical_structure, Neurology, Oncology, Cerebral blood flow, Research Design, Cerebrovascular Circulation, Drug delivery, Neurology (clinical), business, Neoplasm Transplantation
Abstract

We used double-label quantitative autoradiography to measure blood flow (with 131I-iodoantipyrine) and blood-to-tissue transport of 14C-alpha aminoisobutyric acid, AIB) in thirteen 9L gliosarcomas transplanted intracerebrally into Fischer-344 rats. Microscopically, the typical pattern of 9L tumor growth was observed: a solid central tumor mass surrounded by extensive perivascular invasion. The averaged mean whole tumor transfer constant, K, of AIB in the 9L tumors was 33 +/- 15 (+/- SD) microliters/g/min. The averaged mean value of blood flow, F, was 72.2 +/- 27.3 ml/100 g/min. In brain around tumor (BAT), K (13 +/- 4 microliters/g/min) was lower than in the solid tumor, but was still 6-9 times that of tumor-free brain. F in BAT (115.9 +/- 64.6 ml/100 g/min) was comparable to values in tumor-free cortex in the same hemisphere. Values of K and F were used to calculate a net extraction fraction (En) for different regions of brain and tumor. The value of En of AIB in normal cortex was 0.003, in BAT En was 0.02, and in whole tumor the value was 0.09. The delivery of water-soluble compounds in 9L brain tumors is limited by the permeability/surface area characteristics of the tumor capillaries. The properties of blood-to-tissue transport and blood flow of 11 different brain tumor models are compared, and discussed with regard to the choice of brain tumor models for drug delivery research. The 9L brain tumor model is comparable to other transplanted rat brain tumor models, although the extent of tumor cell invasion into BAT makes this model distinctive. However, with regard to blood-to-tissue transport the 9L model differs from autochthonous models and transplanted human glioma models. We discuss guidelines for selecting brain tumor models with which to study the problem of drug delivery to brain tumors.

Published
1991

18. Letter to the editor

Author

Peter C. Warnke, Friedrich W. Kreth, and Ostertag Cb

Subjects
Oncology, medicine.medical_specialty, business.industry, Long term follow up, Internal medicine, Glioma, medicine, Surgery, Neurology (clinical), medicine.disease, business
Published
1994

Catalog

Books, media, physical & digital resources
See catalog results